Verona Pharma (VRNA)

• Market cap: $4.25B
• 1 day: -3.26%
• 5 days: 15.00%
• 1 month: 24.56%
• 3 months: 49.71%
• 6 months: 127.19%
• Year to date: 7.66%
• 1 year: 200.99%
• 5 years: 802.43%
• 10 years: 284.37%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.

Employees: 79

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

142% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 19

102% more capital invested

Capital invested by funds: $965M [Q2] → $1.94B (+$979M) [Q3]

57% more funds holding in top 10

Funds holding in top 10: 7 [Q2] → 11 (+4) [Q3]

21% more funds holding

Funds holding: 123 [Q2] → 149 (+26) [Q3]

0% less call options, than puts

Call options by funds: $27.5M | Put options by funds: $27.6M

0.73% less ownership

Funds ownership: 11.11% [Q2] → 10.38% (-0.73%) [Q3]

11% less repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 46

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $42 19% downside
• Avg. target: $57 10% upside
• High target: $74 43% upside

5 analyst ratings

• positive: 5 100%
• neutral: 0 0%
• negative: 0 0%

Roth MKM Boobalan Pachaiyappan 50% 1-year accuracy 4 / 8 met price target	31% upside $68	Buy Initiated	10 Jan 2025
Wells Fargo Tiago Fauth 50% 1-year accuracy 11 / 22 met price target	43% upside $74	Overweight Maintained	8 Jan 2025
Truist Securities Joon Lee 49% 1-year accuracy 20 / 41 met price target	10% upside $57	Buy Reiterated	8 Jan 2025
HC Wainwright & Co. Raghuram Selvaraju 38% 1-year accuracy 119 / 312 met price target	19% downside $42	Buy Maintained	5 Nov 2024
Canaccord Genuity Edward Nash 56% 1-year accuracy 10 / 18 met price target	15% downside $44	Buy Maintained	5 Nov 2024